ClinicalTrials.gg
RecruitingNCT07426952WeCan-RuralUpdated Oct 16, 2026

Weight Management After Cancer for Survivors in Rural Communities

An interventional study of WeCan-Rural Program in Breast Cancer Survivorship, Weight Management and Cardiovascular (CV) Risk, sponsored by Duke University. Recruiting at 5 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Duke University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Breast Neoplasms by Duke University — 8 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Duke University.

Planned enrollment
27th of 58
40 · median 40
Started
2026
with 6 others
No phase
39 of 69
6 open now
Registered
67th of 69
by date

Among the 69 studies in Breast Neoplasms by Duke University, this one is the 27th largest by planned enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2026, is one of 39 with no phase, and was the 67th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 69 studies in Breast Neoplasms by Duke University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Breast Neoplasms by Duke University, or all of them as a file.
02

Study summary

This study is testing a new program called WeCan-Rural, designed to help breast cancer survivors manage symptoms and build healthy habits like eating well, staying active, and managing their weight. These changes may help lower the risk of heart disease after cancer treatment.

The study will answer two main questions:

  • Can study team successfully recruit and keep participants in the study, and will the participants find the program helpful and easy to follow?
  • Will participants who join the program see better results in areas like weight, symptoms, diet, physical activity, and confidence in managing the participant's health compared to those who receive standard care?

Here's what participants will do:

  • Visit the participant's clinic twice (about 12 weeks apart) to be weighed, have the blood pressure checked, give a blood sample, and complete a short walking test
  • Fill out online surveys about the participant's health, diet, physical activity, symptoms, and confidence in managing the participant's health
  • Be randomly assigned (like flipping a coin) to either receive the WeCan-Rural program or standard health information
  • If assigned to the program, attend 12 weekly one-hour video sessions on Zoom with a trained therapist
Read the detailed description

Breast cancer survivors often face long-term health challenges after treatment, including a higher risk of heart disease. This risk is especially high for women living in rural areas, where access to healthcare and healthy food may be limited, and opportunities for physical activity may be harder to find. Many survivors also deal with ongoing symptoms like pain, fatigue, and emotional distress, which can make it harder to eat well, stay active, and manage their weight.

This study will test a program called WeCan-Rural, designed to help breast cancer survivors improve their health and lower their risk of heart disease. The program teaches skills for healthy eating, physical activity, and managing symptoms that can get in the way of a healthy lifestyle. It includes 12 weekly sessions delivered remotely through Zoom, so participants can join from home. Each session lasts about an hour and covers topics like nutrition, exercise, and ways to cope with symptoms using strategies like relaxation and pacing.

Participants will receive tools to help them track their progress, including a wireless activity tracker, a scale, and a blood pressure monitor. They'll also get printed materials and access to online videos showing how to do recommended exercises. If needed, participants will be provided with a tablet and data plan to make sure they can join the sessions.

The study will include 40 breast cancer survivors who have completed treatment and are living in rural, medically underserved areas. Half will receive the WeCan-Rural program, and half will receive standard health information from the National Cancer Institute. Researchers will look at how easy it is to recruit and keep participants in the program, how satisfied participants are with it, and whether it helps improve the participant's weight, symptoms, diet, physical activity, and confidence in managing the participant's health. The study will also measure changes in heart health indicators like blood pressure, cholesterol, and blood sugar.

If the program is found to be helpful and well-received, it may be tested in a larger study in the future.

03

Conditions studied

  • Breast Cancer Survivorship
  • Weight Management
  • Cardiovascular (CV) Risk
  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 18 years or older
  • female (biological sex)
  • diagnosis of stage I-III breast cancer
  • completed treatments with curative intent (with the exception of hormonal treatments) in the last 5 years
  • >30
  • healthy enough to participate in home-based physical activity
  • able to speak/read English
  • reports rating of ≥4 (i.e., moderate or more severe) out of 10 for one or more of the following symptoms at its worst in the last month (per the MD Anderson Symptom Inventory): pain, fatigue, sadness, and/or distress

Exclusion criteria

Exclusion Criteria:

  • visual, hearing or cognitive impairment or severe mental illness interfering with participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    WeCan-Rural

    Participants will receive the WeCan-Rural intervention, which includes twelve sessions delivered remotely (i.e., videoconferencing) by a trained therapist.

    Behavioral: WeCan-Rural Program

  • No intervention
    Control

    Participants will receive the National Cancer Institute-developed booklet "Facing Forward: Life After Cancer Treatment," which presents information about cancer survivorship topics.

Interventions

  • BehavioralWeCan-Rural Program

    The WeCan-Rural program includes 12, one-hour weekly sessions via Zoom that help breast cancer survivors manage symptoms like pain, fatigue, and emotional distress, while also building healthy habits around eating, exercise, and weight management.

06

What researchers measure

Primary outcomes

  1. Satisfaction with Treatment and Interventionist as measured by the Satisfaction with Therapy and Therapist Scale-Revised (STTS-R)

    Participants will complete the 13-item Satisfaction with Therapy and Therapist Scale-Revised specific to the program they received. The first 12 items ask participants to rate their agreement with statements related to intervention satisfaction on a 5-point scale ranging from "strongly disagree" (1) to "strongly agree" (5). The 13th item asks "How much did the intervention help with your symptoms?" with 5 answer choices ranging from "made things a lot better" to "made things a lot worse."

    Time frame: Post-treatment (about 12-14 weeks after baseline)

  2. Acceptability as measured by the Treatment Acceptability Questionnaire

    The Treatment Acceptability Questionnaire is a six-item scale assessing participants' views of an intervention as acceptable, ethical, and effective. Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable") and averaged.

    Time frame: Post-treatment (about 12-14 weeks after baseline)

Secondary outcomes

  1. Change in blood pressure (systolic and diastolic)

    Both systolic and diastolic blood pressure will be assessed at the baseline and follow-up assessment.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  2. Change in weight

    Participants will be weighed at each assessment.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  3. Change in total cholesterol

    Cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  4. Change in LDL cholesterol

    LDL cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  5. Change in HDL cholesterol

    HDL cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  6. Change in hemoglobin A1c

    Hemoglobin A1c will be assessed through peripheral blood at the baseline and follow-up assessment.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  7. Change in C-reactive protein

    C-reactive protein will be assessed through peripheral blood at the baseline and follow-up assessment.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  8. Change in high sensitivity troponin

    High sensitivity troponin will be assessed through peripheral blood at the baseline and follow-up assessment.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  9. Change in aerobic capacity and endurance as measured by the 6-Minute Walk Test

    The 6-minute walk test is a self-paced, timed test of the total distance in meters that a patient is able to walk over a six-minute period and assesses the ability to exert effort during activity. Higher values indicate higher aerobic capacity and endurance.

    Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)

  10. Pain severity and interference as measured by the Brief Pain Inventory

    The Brief Pain Inventory will be used to assess pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). This measures includes a body map on which the patient can mark the location(s) in which they are experiencing pain, as well as 8 questions on a scale of 0 to 10 with higher scores indicating worse pain severity or pain interference.

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  11. Emotional distress as measured by PROMIS Depression Short Form

    Depressive symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form, an 8-item measure assessing symptoms of depression in the last week. Responses are on a 5-point scale from "never" (1) to "always" (5).

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  12. Emotional distress as measured by PROMIS Anxiety Short Form

    Symptoms of Anxiety will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form, an 8-item measure assessing symptoms of anxiety in the last week. Responses are on a 5-point scale from "never" (1) to "always" (5).

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  13. Fatigue as measured by PROMIS Fatigue Scale

    Fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, a 6-item self-report measure of fatigue. Participants are asked to think about the last week when responding to each item (e.g., "In the past 7 days, how run-down did you feel, on average?"), providing ratings on a scale from "not at all" (1) to "very much" (5).

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  14. Diet as measured by the Dietary Screener Questionnaire

    The Dietary Screener Questionnaire is a 25-item measure asking participants to rate on the frequency of eating/drinking certain foods in the last week.

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  15. Eating behavior as measured by the Three Factor Eating Questionnaire

    Eating behaviors will be assessed using the Three Factor Eating Questionnaire (TFEQ). The 21-item short-form will be used for the present study. The TFEQ measures three domains of eating behavior: 1) cognitive restraint, 2) uncontrolled eating, and 3) emotional eating.

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  16. Physical activity as measured by the Stanford Leisure-Time Activity Categorical Item (L-Cat)

    The L-Cat is a measure of physical activity. Individuals identify which descriptive category best describes their level of activity during leisure time in the last month. Descriptive categories range from inactive to very active.

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  17. Patient self-efficacy for chronic disease coping as measured by Self-Efficacy for Managing Chronic Illness Scale

    The 6-item Self-Efficacy for Managing Chronic Illness Scale will be used to assess participants' current confidence in their ability to prevent symptoms (e.g., pain, fatigue, distress) from interfering with life. Responses are on a 10-point scale from "not at all confident" (1) to "totally confident" (10).

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  18. Patient self-efficacy for managing chronic conditions as measured by the PROMIS Self-Efficacy for Managing Symptoms Short Form

    The 4-item PROMIS Self-Efficacy for Managing Symptoms will be used to assess participants' confidence in their ability to manage symptoms (e.g. during daily activities, in a public place). Items are scored on a 5-point Likert scale, with higher scores indicating greater confidence.

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

  19. Weight-related self-efficacy as measured by the Weight Efficacy Lifestyle Questionnaire

    The Weight Efficacy Lifestyle Questionnaire is an 8-item measure of eating self-efficacy. Participants are asked to provide information about how certain they are that they can resist overeating in difficult situation (e.g., over the weekend, when tired, etc.). Response choices range from 0= "not at all confident" to 10= "very confident."

    Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)

Other outcomes

  1. Food environment as measured by the Perceived Nutrition Environment Measure

    The Perceived Nutrition Environment Measure includes 53 core items to assess three types of perceived nutrition environments: community nutrition environment, consumer nutrition environment, and home food environment.

    Time frame: Baseline

  2. Assessment of rurality as measured by selected items from the Rural Active Living Perceived Support Scale

    Time frame: Baseline

  3. Health literacy as measured by Medical Term Recognition Test (METER)

    The METER will be used to assess health literacy. Participants are asked to review a list of 40 words and check off those that they recognize as actual words, yielding a total score from 0 to 40. 0-20 points: Low health literacy; 21-34 points: Marginal health literacy; 35-40 points: Adequate health literacy

    Time frame: Baseline

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 4 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Feb 23, 2026
StartActual
Aug 31, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07426952
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Aug 31, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Smrithi Divakaran, MPH
Contact
smrithi.divakaran@duke.edu
919-681-7695
Michael W Willis
Contact
michael.w.willis@duke.edu
919-681-8437
Caroline Dorfman, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion